Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets
Safety and efficacy of burosumab in improving phosphate metabolism, bone [...]
Safety and efficacy of burosumab in improving phosphate metabolism, bone [...]
Diagnosis, treatment, and management of rickets: a position statement from [...]
Intact FGF23 concentration in healthy infants, children, and adolescents, and [...]
Serum 25-hydroxyvitamin D threshold and risk of rickets in young [...]
Osteogenesis imperfecta, late or absent diagnosis for mild forms Tabloid [...]
Ligamentous laxity in children with achondroplasia: Prevalence, joint involvement, and [...]
Impressive clinical improvement and disappearance of neuropathic pain in an [...]
ERDERA has launched a new online survey to explore [...]
ERN BOND network and CPMS 2.0 5th Meeting on Rare [...]
A major step forward for collaboration in the care of [...]

ERN-BOND is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are Funded by the European Commission. For more information about the ERNs and the EU health strategy, please visit ec.europa.eu/health/ern
Funded by the European Union
ERN BOND Specific Grant Agreement no. 101157116

Coordinating Center
Istituto Ortopedico Rizzoli
via G.C.Pupilli, 1 – 40136 Bologna – Italy
“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.”

Co-funded by the European Union
ERN BOND Specific Grant Agreement no. 101157116

Coordinating Center
Istituto Ortopedico Rizzoli
via G.C.Pupilli, 1 – 40136 Bologna – Italy
The contents of this website represents the views of the network and is its sole responsibility; and do not necessarily reflect the opinion of the European Union
Privacy and cookie policy